SciTech

Supply Chain

Abstract<br />Kolliphor® HS 15 is an exceptional solubilizer with attributes suited for parenteral and oral formulation of poorly soluble molecules. As a consequence, it is primarily used in screening of new chemical entities (NCEs) and also used as a vehicle in delivery of molecules encapsulated in micelles or micro-emulsions. Its physicochemical and...

Kolliphor® HS 15 - an Enabler for Parenteral and Oral Formulations

Explore the principles and provisions of Section 4 of the UK Corporate Governance Code to enhance your organization's audit, risk, and internal control systems.
Fint out more
Loading ...
Overview
Strengthening audit, risk, and internal control
This whitepaper delves into Section 4 of the UK Corporate Governance Code, which focuses on audit, risk ma

Navigating assurance: Unveiling Section 4 of the UK Corporate Governance Code

Warnings and insurance
Still current at:
10 May 2025
Updated:
Latest update:
Update to information related to increasing tensions between India and Pakistan.
Your travel insurance could be invalidated if you travel against advice from the Foreign, Commonwealth & Development Office (FCDO).
Areas where FCDO advises against travel
Pakistan-Afghanistan

Pakistan

You are exclusively invited to experience Ideagen Huddle, the transformative solution for efficient and secure collaboration. Sign up today to enjoy complimentary access for your entire department – a unique offer available only to Ideagen customers.
Get your free trial
Why Ideagen Huddle?
By evaluating Ideagen Huddle at no cost, you will discover

A pioneer and leader in cloud collaboration and digital client engagement

As environmental, social, and governance (ESG) issues gain prominence, internal audit plays a critical role in driving sustainability, ensuring transparency, and meeting regulatory expectations.
Find out more
Loading ...
overview
Why corporate sustainability is a business imperative
This whitepaper assesses how internal audit can support businesses

The growing urgency of corporate sustainability: The role of internal audit in ESG maturity

Whether you’re responding to a €30M RFP in government contracting or a tightly scoped SaaS vendor selection in financial services, proposal reviews can get messy fast. Disjointed feedback, conflicting edits, outdated versions and compliance gaps are more than just frustrating—they’re risky. Poor quality documents and missed deadlines lead to lost b

Five productivity hacks to streamline proposal collaboration and win more business

Q1 2025 Qualitative Update replay is available for seven days here. The password is Q12025.
20 – 21 May, Virtual Australia Roadshow (Redburn)
26 May, Geneva Roadshow (ZKB), Geneva (CH)
27 – 28 May, Deutsche Bank European Champions Conference, Frankfurt (DE)
11 June, ODDO Interlaken Conference, Interlaken (CH)
19 June, J.P. Morgen European Healthcar

Agenda and Events

We are delighted to kick off our 75th anniversary celebrations today. We would like to take this special year as an opportunity to reflect on the most important milestones in our history and to celebrate the successes we have achieved together.
When courage and passion meld, when pioneering spirit and expertise meet, and when those who get things d

75 years of Vetter: A success story built on courage, passion, and a sense of responsibility

Copyright © 2024 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy.
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.
Copyright © 2024 Rodman Media. All rights reserved. Use of this constitutes acceptance o

research agreement Archives

Details of the application
The Environment Agency has received a new bespoke application for an environmental permit under the Environmental Permitting (England and Wales) Regulations 2016 from Mrs Sarah Dallas.
Application number
EPR/MB3646KL/A001
Regulated facility type
BS12566 Package treatment plant
Regulated facility address
The Grange
Zouches

LU1 4AP, Mrs Sarah Dallas: environmental permit application advertisement - EPR/MB3646KL/A001

Summary of risk management plan for ZINFORO
This is a summary of the risk management plan (RMP) for ZINFORO. The RMP details
important risks of ZINFORO, how these risks can be minimised, and how more information
will be obtained about ZINFORO's risks and uncertainties (missing information).
ZINFORO's SmPC and its package leaflet give essential info

SUMMARY OF THE RISK MANAGEMENT PLAN

Oculis Holding (Nasdaq: OCS) reported a net loss of $36 million for the first quarter of 2025, more than double the loss in the same period last year, as the Swiss biopharma stepped up investment in its late-stage pipeline.
Operating expenses for the quarter rose 30% to $22 million, driven by a 36% increase in research and development spending. The

Oculis posts widening quarterly loss as R&D spend climbs

Jovarn Esterine (18), from Wolverhampton, has had his sentence increased by two years after the Solicitor General Lucy Rigby KC MP referred his case to the Court of Appeal under the Unduly Lenient Sentence scheme.
The court heard that on 7 March 2024, Harleigh Hepworth and Harleigh’s friend travelled to Wolverhampton where they met Esterine and ano

Violent man's sentence increased after fatal stabbing

!!!
Risk management plans (RMPs) for centrally authorised medicines
RMPs reviewed for new medicines
RMPs reviewed for authorised medicines
Safety signals
Started
Ongoing and concluded
Post-authorisation safety studies (PASSs)
Protocols for imposed studies reviewed
Results from imposed studies reviewed
Results from non-imposed studies reviewed
Proto

PRAC statistics

Belgium’s largest drugmaker UCB (Euronext: UCB) today revealed that it has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for at-home self-administration with infusion pump or a new manual push syringe method for Rystiggo (rozanolixizumab).
UCB explained that, with this approval, people living with generalized Myas

UCB's Rystiggo gains Japanese approval

May 8, 2025
Pharmaceutical TechnologyPharmaceutical Technology May 2025
Pages: 16-19
Insulin Vial Trapped in Ice for Diabetic Challenges | Image Credit: ©Nisit – stock.adobe.com
While many parenteral products can be stored and shipped in the liquid state at room temperature, some, including most based on biologic drug substances, must be maintained

Parenteral Formulation: Deciding When to Go Frozen or Freeze-Dried

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes over compounded drugs. Understanding the legal landscape can help life science professionals rethink strategies, protect intellectual property, and adap

Navigating The GLP-1 Litigation Landscape

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump administration.
This time it’s Gilead coming to the table with a fresh $11 billion in hand to spend across its manufacturing and research centers in the U.S.
Gilead broke down the new spending routes in a Wednesday release. T

Gilead tees up $11B in new US manufacturing, R&D investments

NewBiologix has granted ReciBioPharm a non-exclusive license to its Xcell-Eng-HEK293 cell line to support the development and manufacturing of adeno-associated virus (AAV)-based gene therapies.
The agreement enables ReciBioPharm, the advanced therapy division of Recipharm, to integrate the high-performance cell line into its global viral vector man

NewBiologix licenses cell line to ReciBioPharm to support AAV therapeutic manufacturing

Gilead Sciences is investing an additional $11 billion into its U.S. operations, the company announced this week, bringing its total investments in U.S. manufacturing and R&D through 2030 to more than $32 billion.
“Our U.S. R&D and manufacturing investments in the U.S. will create $43 billion in value to the U.S. economy over the next five years th

Gilead Sciences Increases Investment in U.S. Operations

Despite cell therapy’s growth and extraordinary potential to treat a wide array of diseases, commercial viability remains an ongoing challenge. Companies are under pressure to demonstrate not just that these therapies work but that they can be manufactured sustainably and at scale. Balancing product quality, regulatory compliance, and cost-effectiv

Is Early Automation The Key To Scalable Cell Therapy Manufacturing?

Process analytic technology monitoring and control (PAT MC) is rapidly progressing as instruments shrink in size and have faster signal acquisition times, analyzers account for more variables, and modeling becomes more machine learning-based. In this environment, it is challenging for pharmaceutical and biopharmaceutical companies to understand the

A Road Map For PAT Monitoring And Control

Duncan Flack from Honeywell will discuss the Circularity in Primary Pharmaceutical Packaging Accelerator, which provides a great example of how an industry is calling upon its stakeholders to take account of the waste packaging that it generates.
PRS
The third annual Packaging Recycling Summit is next month, June 25-27, 2025 at The Ritz-Carlton Dal

PRS Session Highlight: How to Deliver Pre-Competitive Collaboration Across the Pharma Industry

Thursday, May 08, 2025
ViVerita Therapeutics has announced a new research collaboration with Boehringer Ingelheim.
The partnership aims to speed up the discovery and validation of new therapeutic targets in cancer treatment.
As part of the agreement, ViVerita will use its advanced in vivo CRISPR-based discovery platform to study a selection of pote

ViVerita Therapeutics Enters into Collaboration with Boehringer Ingelheim to Discovery of Novel Cancer Targets

Medicines for Europe calls for continued progress of pharmaceutical reforms such as the Critical Medicines Act, to support production of essential medicines in the region.
As EU Health Ministries approach the final stages of negotiations on the future of Europe’s pharmaceutical rules, Medicines for Europe has called for key actions to ensure medici

Tackling EU supply chain challenges while boosting innovation

Brazil’s drug pricing authorities are planning to introduce a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.
Key Takeaways
A drug pricing shakeup in Brazil would ensure that companies submit more “robust” information for drug pricing decisions.
A draft resolutio